AI SummaryThis article discusses the development of CD45-targeted immunocytokines in cancer immunotherapy. These fusion proteins have the potential to reprogram anti-tumor immunity by staying on T cells and dendritic cells for longer periods while reducing systemic toxicities through direct delivery into tumors.Immunocytokines are cytokine-based fusion proteins with therapeutic potential. New CD45-targeted immunocytokines can reprogram systemic… Continue reading CD45 threads the needle of cytokine cancer immunotherapy
Tag: Cancer Immunotherapy
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade
AI SummaryThis article discusses the role of angiotensin receptor blocker (ARB) in attacking armored and cold tumors and enhancing the efficacy of immune checkpoint blockade (ICB) therapy. The study found that ARB targets angiotensin II receptor 1 (AGTR1), which is overexpressed in armored and cold tumors and associated with poor response to ICB therapy. ARB… Continue reading Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
AI SummaryThis article discusses the use of MHC class I and II-deficient humanized mice as tools to study the long-term efficacy of immune checkpoint inhibitors and T-cell engagers in cancer immunotherapy. The study explores different strategies to overcome xenograft-versus-host disease (xGVHD) in immunodeficient mice engrafted with human PBMCs and co-engrafted with tumor cells. The results… Continue reading MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
AI SummaryThis article discusses the durability of response to immune checkpoint blockade (ICB) following treatment discontinuation in patients with advanced Merkel cell carcinoma (MCC). The study found that patients who achieved a complete response (CR) had a lower rate of progression compared to those who did not, and those who discontinued treatment electively had a… Continue reading Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
AI SummaryThis study focuses on Lynch syndrome and somatic mismatch repair variants in pancreas cancer. It examines clinicogenomic features and explores responses to immune checkpoint blockade therapy. The research aims to provide insights into the genetic and clinical characteristics of Lynch syndrome in pancreas cancer patients and their response to treatment.This cross-sectional study examines clinicogenomic… Continue reading Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
Researchers reveal key LAG3 mechanisms that could transform cancer immunotherapy
AI SummaryResearchers have discovered key mechanisms of LAG3, a protein that suppresses the antitumor immune response, which can improve cancer immunotherapy by enhancing the effectiveness of immune checkpoint inhibitors.Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this… Continue reading Researchers reveal key LAG3 mechanisms that could transform cancer immunotherapy
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
AI SummaryThis study examines the immunogenicity and efficacy of the XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters. The researchers aim to determine the effectiveness of the vaccine against this specific variant of the virus in animal models. The results will provide important insights into the potential of this vaccine to… Continue reading Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
AI SummaryThis study focused on the use of IL-33 targeting to enhance the antitumor response to anti-PD-L1 immunotherapy by reprogramming the tumor microenvironment. The research demonstrated that blocking IL-33 using a fusion protein in combination with anti-PD-L1 treatment increased T cell responses, inhibited tumor progression, and provided long-term protective immunity. Targeting both IL-33 and PD-L1… Continue reading Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
AI Summary, and ICIs may have synergistic effects in ovarian cancer patients. Tailored immunotherapy approaches based on individualized immunophenotypes and genetic data could improve patient outcomes and guide future treatment strategies. Advanced tissue-based profiling and collaborative research efforts are essential for the successful implementation of immunotherapy in ovarian cancer.Abstract Despite documented evidence that ovarian cancer… Continue reading Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
AI SummaryThe article discusses the findings of a clinical trial (MARIO-3) investigating the combination of the PI3K-inhibitor eganelisib with immune checkpoint inhibitor therapy and chemotherapy in metastatic triple-negative breast cancer (TNBC). The results show that this combination triggers reprogramming of tumor-associated macrophages (TAMs), immune activation, and extracellular matrix reorganization in the tumor microenvironment. Gene signatures… Continue reading Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment